This content is machine translated BRAFV600 stage IV melanoma Targeted therapy: “real world” data on encorafenib plus binimetinib The BERING-Melanoma multicenter study is monitoring the use of encorafenib with binimetinib in the first- and second-line setting* in patients with advanced BRAFV600-mutated malignant melanoma in everyday care in Germany, Austria,…
View Post 8 min This content is machine translated Plasma cell myeloma Preferences in myeloma treatment in Switzerland 2018 With the approval of several new drugs, the treatment spectrum for second-line therapy of plasma cell myeloma has been expanded. In parallel, established treatment concepts, predominantly in first-line treatment, were…
View Post 6 min This content is machine translated DGHO in Vienna Prostate and breast cancer: the future belongs to combined therapies Treatment options are often limited in both prostate and breast carcinoma. The search for new effective drugs and combination therapies is therefore the primary goal of current studies.
View Post 4 min This content is machine translated Annual Meeting DGHO, OeGHO, SGMO and SGH+SSH in Stuttgart, Germany Update hepatocellular carcinoma – news from the system therapy In hepatocellular carcinoma, an increase in incidence has been observed in industrialized countries. HCC patients have at least two diseases, namely carcinoma as well as severe liver disease. The interaction…
View Post 4 min This content is machine translated PD1/PD-L1 in second-line therapy for metastatic NSCLC. The agony of choice The treatment of bronchial carcinoma is greatly changed by immunotherapy. Current developments will lead to an adjustment of our therapy algorithms in the coming months.
View Post 7 min This content is machine translated HER2-positive breast carcinoma New substances enable targeted therapy The HER2 receptor belongs to the family of four transmembrane receptor tyrosine kinases (EGFR/HER1, HER2, HER3, and HER4) that influence cell growth, differentiation, and survival. Overexpression of HER2 occurs in…
View Post 4 min This content is machine translated HER2-positive breast cancer and lymphoma New applications and antibodies The antibody-drug conjugate trastuzumab emtansine, T-DM1 (Kadcyla®), is composed of the antibody trastuzumab and the chemotherapeutic agent DM1 and is currently being investigated for the treatment of HER2-positive cancers. It…
